As of 2025-05-18, the Intrinsic Value of Tianda Pharmaceuticals Ltd (455.HK) is 0.00 HKD. This 455.HK valuation is based on the model Discounted Cash Flows (EBITDA Exit 10Y). With the current market price of 0.16 HKD, the upside of Tianda Pharmaceuticals Ltd is -99.40%.
The range of the Intrinsic Value is (0.03) - 0.04 HKD
Based on its market price of 0.16 HKD and our intrinsic valuation, Tianda Pharmaceuticals Ltd (455.HK) is overvalued by 99.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (4.62) - (0.36) | (0.63) | -509.5% |
| DCF (Growth 10y) | (0.17) - (1.29) | (0.24) | -255.4% |
| DCF (EBITDA 5y) | (0.03) - 0.02 | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (0.03) - 0.04 | 0.00 | -99.4% |
| Fair Value | -0.14 - -0.14 | -0.14 | -192.08% |
| P/E | (0.24) - (0.27) | (0.27) | -271.7% |
| EV/EBITDA | (0.12) - 0.05 | (0.06) | -138.7% |
| EPV | (0.66) - (0.93) | (0.80) | -615.0% |
| DDM - Stable | (0.53) - (4.13) | (2.33) | -1603.2% |
| DDM - Multi | (0.20) - (1.27) | (0.35) | -328.3% |
| Market Cap (mil) | 333.26 |
| Beta | 0.39 |
| Outstanding shares (mil) | 2,150.04 |
| Enterprise Value (mil) | 375.01 |
| Market risk premium | 5.98% |
| Cost of Equity | 5.93% |
| Cost of Debt | 5.50% |
| WACC | 5.68% |